<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>In Abstract</provider_name><provider_url>https://www.mub.eps.manchester.ac.uk/in-abstract</provider_url><author_name>Enna Bartlett</author_name><author_url>https://www.mub.eps.manchester.ac.uk/in-abstract/author/ennabartlett/</author_url><title>Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals - In Abstract</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="JPEEJnyAFO"&gt;&lt;a href="https://www.mub.eps.manchester.ac.uk/in-abstract/arylation-of-pharmaceuticals/"&gt;Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.mub.eps.manchester.ac.uk/in-abstract/arylation-of-pharmaceuticals/embed/#?secret=JPEEJnyAFO" width="600" height="338" title="&#x201C;Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals&#x201D; &#x2014; In Abstract" data-secret="JPEEJnyAFO" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://www.mub.eps.manchester.ac.uk/in-abstract/wp-content/uploads/sites/61/2018/08/Cyclometallated-ruthenium-catalyst-enables-late-stage-directed-arylation-of-pharmaceuticals.jpg</thumbnail_url><thumbnail_width>890</thumbnail_width><thumbnail_height>350</thumbnail_height><description>New class of ruthenium catalysts allows late-stage arylation of drugs Most drugs and other biologically active compounds incorporate a large number of polar functional groups, which are responsible for the observed activity. However, the presence of these polar groups increase difficulty for chemists to modify these compounds as often transition metal catalyst will be incompatible [&hellip;]</description></oembed>
